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Enhanced Death Ligand-Induced Apoptosis in
Cutaneous SCC Cells by Treatment with
Diclofenac/Hyaluronic Acid Correlates with
Downregulation of c-FLIP
Lothar F. Fecker1, Eggert Stockfleth1, Frank K. Braun1, Paul M. Rodust1, Constanze Schwarz1, Anja Ko¨hler1,
Martin Leverkus2 and Ju¨rgen Eberle1
Actinic keratosis (AK) occurs on sun-exposed skin and may progress to invasive squamous cell carcinoma
(SCC). As for its topical treatment, diclofenac/hyaluronic acid (HA) has been recently approved. The NSAID
diclofenac is an inhibitor of COX-2; however, its mode of action in cutaneous epithelial cancer cells is largely
unknown. Here, the effects of diclofenac/HA were investigated in relation to death ligand-mediated apoptosis
(TNF-a, TRAIL, and CD95 activation). Whereas diclofenac/HA only moderately induced apoptosis by itself, it
resulted in pronounced enhancement of death ligand-mediated apoptosis in sensitive SCC cell lines (3/4).
Apoptosis was associated with activation of initiator caspases of the extrinsic pathway (caspase-8/caspase-10).
Furthermore, death ligand and diclofenac/HA-mediated apoptosis were blocked by the same caspase inhibitors,
indicating related pathways. The proapoptotic effects of diclofenac/HA appeared independent of the p53
pathway. Also, upregulation of death receptors appeared less important; however, strong downregulation of
c-FLIP isoforms was seen after diclofenac/HA treatment. The crucial role of c-FLIP was proven through
overexpression and knockdown experiments. Thus, induction of apoptosis appears to be highly characteristic
of the mode of action of diclofenac/HA, and the therapeutic effect may be related to sensitization of neoplastic
keratinocytes for death ligand-induced apoptosis.
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INTRODUCTION
The incidence of actinic keratosis (AK) has dramatically
increased in last decades and is closely related to UV
irradiation as well as immune suppression (Ulrich et al.,
2006; Stockfleth et al., 2008). AK lesions, which derive from
neoplastic epidermal keratinocytes, are primarily restricted
to the epidermis; however, they may proceed to invasive
squamous cell carcinoma (SCC). Therefore, and due to
histological and molecular correspondence, AK is considered
by some researchers a carcinoma in situ and an early stage
of invasive SCC (Quatresooz et al., 2008; Hauschild
et al., 2009). Topical 3% diclofenac sodium in 2.5%
hyaluronic acid solution (diclofenac/hyaluronic acid (HA),
Solaraze) has been approved as a new treatment for AK and
has shown significant efficacy (Merk, 2007; Stockfleth et al.,
2008).
Apoptosis is fundamental in controlling tissue homeostasis
(Kerr et al., 1972), and resistance to apoptosis appears to be a
crucial step in oncogenesis (Fischer and Schulze-Osthoff,
2005; Eberle et al., 2007). Multiple pathways are used in
apoptosis regulation. Thus intrinsic apoptosis pathways are
activated in response to cellular stress such as DNA damage,
also considered characteristic of the mode of action of
many chemotherapeutics (Fulda and Debatin, 2006). Often
after p53 activation, intrinsic apoptosis relies on increased
mitochondrial outer membrane permeability and release
of mitochondrial factors such as cytochrome c, which triggers
activation of the initiator caspase-9 (Chipuk and Green,
2008).
On the other hand, death ligand-mediated, extrinsic path-
ways are of particular importance for apoptosis induced by
cytotoxic T-lymphocytes and natural killer cells in an
immune response (Russell and Ley, 2002; Dauer et al.,
2005). Upon the binding of death ligands such as tumor
necrosis factor-a (TNF-a), CD95L/FasL, or TRAIL to respective
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death receptors (TNF-R1, CD95, TRAIL-R1/DR4, and TRAIL-
R2/DR5), intracellular protein complexes (death-inducing
signaling complex) are formed. Here, initiator caspase-8
and caspase-10 are activated (Krammer et al., 2007). These
initiator caspases start a signaling cascade, which leads to
activation of effector caspases as caspase-3, 6, and 7, which
cleave a large number of death substrates to set apoptosis into
work (Fischer et al., 2003). Effector caspases and caspase-9
may be blocked by inhibitor of apoptosis proteins, whereas
activation of caspase-8 and caspase-10 is inhibited by
competitive binding of the long or the short isoform of
cellular FLICE-inhibitory protein (c-FLIPL/S) to the death-
inducing signaling complex (Nachmias et al., 2004; Krammer
et al., 2007). The death ligand-mediated pathways may be
further enhanced by cleavage and activation of the proapop-
totic Bcl-2 protein Bid through caspase-8 (Ward et al., 2006).
Overexpression of antiapoptotic factors and apoptotic defi-
ciency of tumor cells may result from activation of different
survival pathways, including nuclear factor-kB, mitogen-
activated protein kinases and PI3/Akt (Eberle et al., 2007).
The mode of action of diclofenac/HA in cutaneous AK is
largely elusive. A main target of the non-steroidal anti-
inflammatory drug (NSAID) diclofenac is cyclooxygenase-2
(COX-2), which is overexpressed in epithelial tumors (Fecker
et al., 2007). HA is supposed to keep diclofenac in the
epidermis, thereby prolonging its pharmacokinetic half-life
(Moore and Willoughby, 1995). As a ligand of CD44, HA
may further contribute to modulation of the immune response
in the in vivo situation (Larkin et al., 2006). Multiple relations
between COX-2 and other survival pathways as mitogen-
activated protein kinases and PI3K/Akt have been reported,
and we have previously described induction of apoptosis by
diclofenac/HA in SCC cell lines (Fecker et al., 2007).
Due to the crucial role of the immune system in
protection from AK and subsequent invasive SCC, as seen
in chronic immune-suppressed patients (Ulrich et al., 2006),
the relationship of diclofenac/HA to extrinsic apoptotic
pathways was of particular interest. It was investigated here
via combined treatment of SCC cells with diclofenac/HA and
death ligands, and by unraveling the subsequent pathways.
RESULTS
Sensitivity of SCC cells to death ligands
For investigating the activity of extrinsic proapoptotic
signaling cascades in SCC cells and their general apoptosis
sensitivity, SCL-I, SCL-II, SCC-12, and SCC-13 cell lines were
treated with death ligands. Application of an agonistic CD95
antibody (CH-11), TRAIL, and TNF-a significantly enhanced
DNA fragmentation, indicative of apoptosis, thus indicating
the presence of open extrinsic apoptosis pathways in these
cells (Figure 1a). As pilot experiments had shown particularly
high sensitivity of SCC-12, they were generally treated with
reduced doses of CH-11 and TRAIL. Only SCC-13 showed
relatively weak response to TNF-a and CH-11. In general,
TRAIL appeared to be most effective in SCC cells (Figure 1a).
Access of the proapoptotic caspase cascades was evident
by generation of caspase cleavage products. Enhanced
apoptosis in SCL-I, SCL-II, and SCC-12 cells by CH-11 and
TRAIL was associated with significant processing of initiator
caspase-8 and effector caspase-3. By contrast, weak induc-
tion of apoptosis in SCC-13 also coincided with weak
caspase processing (Figure 1b).
Activation of extrinsic apoptosis pathways by diclofenac/HA
Apoptosis induction by diclofenac/HA as associated with
effector caspase-3 activation had been shown previously for
SCL-II, SCC-12, and SCC-13, whereas SCL-I was resistant
(Fecker et al., 2007). Here we present evidence that as well
caspase-8, the initiator caspase of the extrinsic pathway, was
activated by diclofenac/HA. Caspase-8 cleavage products
appeared in parallel to caspase-3 activation after 24 hours
of treatment with 0.2% diclofenac/HA in SCL-II, SCC-12, and
SCC-13, suggesting that diclofenac/HA may mediate its
proapoptotic effects by influencing extrinsic apoptosis path-
ways. Again, caspase-8 activation was absent in SCL-I cells,
indicative of an early block of the diclofenac-mediated effects
in these cells (Figure 2).
Enhanced death ligand-mediated apoptosis by combined
treatment with diclofenac/HA
The relationships between diclofenac/HA and the death
ligands CH-11, TRAIL, and TNF-a were investigated in four
SCC cell lines and in the immortalized keratinocyte cell line
HaCaT. Cells were pretreated for 4 hours with 0.2%
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Figure 1. Death ligand-mediated apoptosis. (a) Cell lines of cutaneous SCC
(SCL-I, SCL-II, SCC-12, SCC-13) were treated for 16 hours with CH-11 and
TRAIL, or for 24 hours with TNF-a, and the relative apoptotic response was
determined by DNA fragmentation analysis and compared with untreated
controls. Three independent experiments for SCL-II, SCC-12, and SCC-13 and
two experiments for SCL-I were performed, each experiment consisting of at
least double values, and means±SD of all experiments are given here.
Induction of apoptosis by all three death ligands in the four cell lines was
statistically significant (*Po0.05). (b) Formation of specific cleavage products
of activated caspase-8 (43, 41, 18 kDa) and of activated caspase-3 (19, 17,
15 kDa) were determined by western blot analysis. Analysis was performed
for SCL-I, SCL-II, SCC-12, and SCC-13 cells after treatment with CH-11,
TRAIL, or TNF-a.
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diclofenac/HA, followed by 16 hours of combined treatment
with diclofenac/HA and death ligands, and apoptosis was
determined by measuring DNA fragmentation.
Strikingly, apoptosis induction by death ligands was strongly
enhanced by combined treatment with diclofenac/HA in
SCL-II, SCC-12, SCC-13, and HaCaT cells. By clear contrast,
no enhancement was seen for SCL-I, showing that this cell line
was not only resistant to diclofenac/HA treatment alone but
also to its enhancing effects (Figure 3a). A similar result was
obtained by cell-cycle analysis after propidium iodide staining.
In parallel to DNA fragmentation analysis, a twofold enhance-
ment of the sub-G1 cell population was observed in SCC-12
cells after combined treatment (diclofenac/HAþCH-11) as
compared with treatment with CH-11 alone. Under the
applied conditions, 15% of the cells were identified in the
sub-G1 population (apoptotic) (Figure 3b).
As positive control for the apoptosis assays, the highly
CH-11-sensitive T-ALL cell line Jurkat was used, and
apoptosis levels were compared to that in SCC-12 cells. As
compared with apoptosis induction in Jurkat cells, SCC cells
had a lower percentage of sub-G1 cells even after combined
treatment. Due to low basal apoptosis in SCC cells, however,
the relative induction of apoptosis as compared with that in
non-treated cells was on a comparable level, as determined
by DNA fragmentation ELISA. This comparison also proved
the reliability of both assays used (Figure 3c).
To determine whether the enhanced apoptosis was also
reflected by reduced cell numbers, cell density was
continuously monitored by real-time cell analysis using
microtiterplates. Diclofenac (90 mgml1) and TRAIL
(20 ngml1) were added to SCC-12 cells 22 hours after
seeding. Within the time period between 20 and 60 hours
after seeding, untreated control cells showed continuous
growth, whereas treatment with TRAIL and diclofenac each
showed significant decreases in cell proliferation. Most
dramatic, however, was the combination of both, which
resulted in a quick (within 15 hours) and almost complete
decrease of attached cell numbers (Figure 3d).
Enhanced caspase activation after combined treatment
Activation of the proapoptotic signaling cascade was
investigated by western blot analysis of SCC-12 cells. The
analysis was performed for the initiator caspases of the
extrinsic pathway (caspase-8 and -10), the initiator caspase of
the intrinsic pathway (caspase-9), for effector caspases
(caspase-3 and caspase-7), and for the mediator between
the extrinsic and intrinsic pathways, the proapoptotic Bcl-2
protein Bid.
Relatively weak bands of caspase cleavage products
indicative of caspase processing/activation were obtained
after treatment with either diclofenac/HA or death ligands
alone. However, significantly enhanced processing of all
caspases and of Bid was observed for the three death ligands
when combined with diclofenac/HA (Figure 4). Thus,
complete activation of caspase pathways was the result of
combined treatment of SCC cells.
Identical patterns of caspase inhibition for diclofenac/HA
and death ligand-induced apoptosis
The pathways used by diclofenac/HA were further characte-
rized by identification of the caspases crucial for apoptosis
induction. We used a panel of selective caspase inhibitors
directed against caspases-1, -2, -3, -4, -6, -8, -9, -10, and -13,
as well as the pancaspase inhibitor zVAD. Whereas caspases-
2, -3, -6, -8, -9, and -10 regulate apoptosis, caspases-1, -4,
and -13 are mainly involved in the regulation of inflammation
and were used here as controls.
When SCC-13 cells were treated with the death ligand
TRAIL, a characteristic inhibition pattern was observed,
namely inhibitors for caspase-3, 8, and 10 as well as zVAD
strongly abrogated apoptosis induced by TRAIL (Figure 5a).
Most interestingly, an almost identical inhibition pattern was
found when these cells were treated with diclofenac/HA
(Figure 5b), indicating the crucial importance of extrinsic
death receptor-related pathways for its mode of action.
Independence of diclofenac/HA proapoptotic effects from p53
As p53 mutations are characteristic of AK and cutaneous SCC
(Ziegler et al., 1994; Nindl et al., 2007), we investigated
whether there was a correlation between the p53 pathway
and diclofenac/HA sensitivity. Using HaCaT cells we
assessed whether diclofenac/HA may exert its effects also in
these p53-mutated, non-malignant keratinocytes. The p53
mutation in HaCaT cells and inactivation of the pathway
have been previously described (Lehman et al., 1993). Quite
similar to sensitive SCC cells, HaCaT cells as well responded
to diclofenac/HA, with enhancement of apoptosis through
death ligands, suggesting that an active p53 pathway was not
needed in these cells for the response (Figure 3a).
Furthermore, sequence analysis of exons-5, 7, and 8 of
p53 was performed for the SCC cell lines and the HaCaT cells
used here. These exons represent conserved domains of p53,
frequently mutated in human tumors (Field et al., 1993).
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Figure 2. Caspase-8 activation by diclofenac/HA. SCC cells were treated
for 24 hours with 0.2% diclofenac/HA (D/HAþ ) and were compared with
untreated controls (). Formation of specific cleavage products are shown
for activated caspase-8 (43, 41, 18 kDa) and caspase-3 (17, 15 kDa), as
determined by western blot analysis. For loading control, blots were
incubated with a b-actin antibody. The experiment was performed twice
starting from independent cell isolates, which gave highly comparable results.
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Whereas SCL-I and SCC-12 showed no mutations in
these p53 exons, characteristic mutations were identified in
SCL-II and SCC-13. The mutation in SCL-II applied to
Lys(132), which was substituted by Asn. In accordance to a
previous report (Burns et al., 1993), we identified a mutation
in SCC-13 resulting in a substitution of Glu(258) by Lys.
Also the mutations previously described for HaCaT cells
(Lehman et al., 1993), namely substitution of His(179) by
Tyr, substitution of Arg(282) by Trp, as well as a silent
mutation at position 281, were approved in our cell line.
As SCL-I was resistant to diclofenac/HA-enhanced apoptosis
and SCC-12 was highly sensitive, the response of SCC
cells again appeared to not be correlated with the p53
mutation status.
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Figure 3. Enhanced apoptosis by combination of diclofenac/HA and death ligands. (a) Apoptosis levels (DNA fragmentation) of SCL-I, SCL-II, SCC-12,
SCC-13, and HaCaT cells are shown without treatment (Control), after treatment with diclofenac/HA (D/HA, 0.2%), after treatment with death ligands (CH-11,
TRAIL, TNF-a), and after combined treatment with diclofenac/HA and death ligands. Diclofenac/HA was administered for 20 hours and death ligands were
applied for 16 hours. The relative values were normalized with respect to untreated controls. Three independent experiments for SCL-II, SCC-12, and SCC-13
and two experiments for SCL-I and HaCaT were performed, each experiment consisting of at least double values. The means±SD of all experiments (SCC) or of
a representative experiment (HaCaT) are given. The enhancement of death ligand-induced apoptosis by diclofenac/HA was statistically significant in all
combinations and all sensitive cell lines (Po0.05), as indicated by asterisks. (b) FACS analyses of propidium iodine-stained SCC-12 cells are shown. Cells were
treated with diclofenac/HA alone (0.2%, 20 hours), CH-11 alone (1 ngml1, 16 hours), or with a combination of both. The percentages of sub-G1 cell
populations (apoptotic cells, values indicated) were compared with untreated controls. The experiment was performed twice starting from independent cell
isolates, which gave highly similar results. (c) Apoptosis induction in SCC-12 by CH-11 was compared with the highly sensitive T-ALL cell line Jurkat, treated
with CH-11 for 16 hours. The upper panel shows relative apoptosis values (x-fold change) as determined by ELISA. The lower panel shows the percentages of
sub-G1 cells as determined by propidium iodide staining and FACS analysis. The experiments were run in parallel and the experiment has been performed twice
resulting in comparable values. Enhancement of apoptosis by CH-11 and by combinations as compared with controls was statistically significant (*Po0.05).
(d) Real-time cell analysis monitoring cell confluence (cell index) over time was performed for SCC-12 cells, which were left untreated (Control), treated with
diclofenac (90 mgml1), with TRAIL (20 ngml1), or with a combination of both, as indicated in the figure. All treatments started at 22 hours. Each value
represents the mean of four wells. The cell index curves were normalized to a value of 1 at 1 hour before treatment started. The experiment was performed with
three different seeding densities (20,000; 10,000; and 5,000 cells per well), of which only the values for 10,000 cells are shown here. The whole experiment was
repeated once. The different seeding densities as well as the second experiment gave similar results.
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Downregulation of the caspase antagonist c-FLIP
As a possible explanation for the enhancing effects on
extrinsic apoptosis pathways, diclofenac might trigger the
expression of TRAIL. In this case, the enhancing effects
should be abrogated by antagonistic TRAIL-receptor anti-
bodies. The antagonistic activity of TRAIL-receptor antibodies
(anti-TRAIL-R1/DR4 and anti-TRAIL-R2/DR5) had been pro-
ven in a previous study (Kurbanov et al., 2005). Apoptosis
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Figure 4. Full activation of the proapoptotic caspase cascade after combined
treatment. SCC-12 cells were treated with diclofenac/HA (D/HA), CH-11,
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ligands. Specific cleavage products of caspases and of Bid were detected by
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caspase-3 (15, 17, 19 kDa), and caspase-7 (19, 30 kDa). For loading control,
blots were incubated with a b-actin antibody. Western blot experiments were
performed twice using independent cell isolates, which resulted in highly
similar results.
TRAIL
Diclofenac/HA
**
**
**
**
**
**
** **
–
– –
+ + + + + + + + + + +
– + + + + + + + + + + +
C13C10C9C8C6C4C3C2C1zV
– – C13C10C9C8C6C4C3C2C1zV
TRAIL
D/HA
Inh
Inh
R
el
. D
N
A 
fra
gm
en
ta
tio
n
R
el
. D
N
A 
fra
gm
en
ta
tio
n
4
3
2
1
0
4
3
2
1
0
Figure 5. Inhibition of TRAIL and diclofenac/HA-induced apoptosis by
caspase inhibitors. SCC 13 cells were treated with TRAIL (20 ngml1,
16 hours, a) or with diclofenac/HA (D/HA, 0.3%, 24 hours, b). In addition,
cells had received treatment with various caspase inhibitors (10 mM). The
inhibitors were applied 1 hour before diclofenac/HA and TRAIL treatment
started and were present during the whole period of treatment. The inhibitors
used were the pancaspase inhibitor zVAD-fmk (zV) and inhibitors regarded as
specific for caspase-1, 2, 3, 4, 6, 8, 9, 10, and 13 (C1–C13). Relative DNA
fragmentation values (apoptosis) are shown in relation to untreated cells,
which were set to 1 (white bars). Note that apoptosis induced by diclofenac/
HA or TRAIL was suppressed by zVAD-fmk as well as by inhibitors of caspase-
3, 8, and 10 (black bars). The whole experiment was performed twice with
triplicate values both times. Both experiments produced highly similar results.
The mean values±SD of one experiment are shown here. Suppression of
apoptosis by zVAD-fmk, C3, C8, and C10 was statistically highly significant
(Po0.01) as indicated by asterisks on the columns.
Figure 6. Changes at the death receptor level. (a) The effects of two antagonistic TRAIL receptor antibodies directed against TRAIL-R1/DR4 (anti-DR4) and
against TRAIL-R2/DR5 (anti-DR5) were investigated in SCC-12 cells, and treated cells were compared with control cells (No antibody). Cells did not receive
any extra treatment, or received in addition TRAIL (20 ngml1, 24 hours) or diclofenac/HA (0.3%, 24 hours), as indicated below. Note that TRAIL-induced
apoptosis was blocked by anti-DR4 but not anti-DR5, and diclofenac/HA treatment resulted in proapoptotic antibody effects. The mean values±SD of an
experiment with triplicate values are shown. The experiment has been repeated three times with single values each time, which gave similar results. Inhibition of
TRAIL-induced apoptosis by TRAIL receptor antibodies as well as enhancement of apoptosis by a combination of diclofenac/HA and antibodies as compared
with diclofenac/HA treatment alone were statistically significant (*Po0.05). (b) Surface expression of CD95, TRAIL-R1, and TRAIL-R2 death receptors was
monitored by flow cytometry using four SCC cell lines without any extra treatment (thin line) and after treatment with 0.3% diclofenac/HA (D/HA, 24 hours;
thick line). Isotypic control antibodies are shown as filled graphs. A shift to the right indicates increased surface expression. The experiment has been repeated
once using independent cell isolates, giving similar results. (c) Expression of c-FLIPL (55 kDa) and c-FLIPS (28 kDa) is shown in four SCC cell lines and in HaCaT
cells as determined by western blot analysis. Cells treated for 24 hours with 0.3% diclofenac/HA (þ ) were compared with untreated control cells ().
For loading control, blots were incubated with b-actin antibody (SCC cells) and a-tubulin antibody, respectively (HaCaT cells). The experiment was performed
three times (SCC cells) and two times (HaCaT), respectively, using independent cell isolates, which gave similar results.
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induced by TRAIL in SCC-12 cells was blocked by an
antagonistic TRAIL-R1 antibody, whereas anti-TRAIL-R2
showed a weaker inhibitory effect. Thus, TRAIL appears to
particularly use TRAIL-R1/DR4 for induction of apoptosis in
SCC-12 cells (Figure 6a).
Concerning diclofenac/HA, both antibodies were unable
to block its proapoptotic effects, thus largely excluding a role
of TRAIL induction in the course of diclofenac/HA treatment.
Strikingly, the antagonistic effects of these antibodies were
converted by diclofenac/HA to a now agonistic, proapoptotic
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activity. Namely, combinations of diclofenac/HA with the
antibodies resulted in significantly enhanced apoptosis
(Figure 6a). Thus, fundamental changes at the death-receptor
level have to be supposed.
Increased death-receptor surface expression was consid-
ered as another possible explanation of enhanced death
ligand sensitivity. FACS analysis of CD95, TRAIL-R1, and
TRAIL-R2 showed their general and significant surface
expression in four SCC cell lines, in agreement with death-
ligand sensitivity. However, only minor changes in the
surface levels of death receptor were seen upon treatment.
Some upregulation occurred also in resistant SCL-I cells, and
mainly TRAIL-R2 expression was changed, which appeared
less involved in TRAIL-mediated apoptosis in SCC cells
(Figure 6b). Thus, some enhancement of death receptor
surface expression by diclofenac/HA treatment might be
contributing but appeared to not be decisive for enhancement
of death ligand sensitivity of SCC cells.
The proapoptotic activity of death receptors is crucially
and negatively regulated by the competitive caspase-8/10
inhibitor c-FLIP. The two isoforms FLIPS and FLIPL may
prevent binding of the initiator caspase to the death-inducing
signaling complex and their activation. All four SCC cell lines
and HaCaT cells were characterized by significant basal
expression levels of FLIPL and FLIPS (Figure 6c). However,
after 24 hours of treatment with diclofenac/HA, both c-FLIP
isoforms were strongly downregulated in apoptosis-sensitive
cell lines SCL-II, SCC-12, SCC-13, and in HaCaT cells.
By clear contrast, no changes in c-FLIP expression were seen
in resistant SCL-I cells (Figure 6c).
Investigating the question whether downregulation of
c-FLIP was only associated or a required event, HaCaT
cells with c-FLIP overexpression (stably transduced with
a retroviral vector) were investigated as compared with
mock-transduced cells. Transduction rates were 480%, as
determined by flow cytometric analysis for green fluorescent
protein (data not shown). In HaCaT-FLIP cells, not only was
apoptosis induction by death ligands blocked, but also the
enhancing effect of diclofenac/HA and direct induction of
apoptosis by Solaraze were not seen. By contrast, HaCaT-1-
Mock-transduced cells showed an enhancement of death
ligand-induced apoptosis by diclofenac/HA (Figure 7a)
similar as that described above for non-transduced HaCaT
cells (Figure 3a). Overexpression of c-FLIPL was proven by
western blot analysis (Figure 7a, inset).
For a complementary approach, we performed cFLIP
knockdown experiments in SCC-12 cells using lentiviral
FLIPRNAi and ScrambleRNAi expression vectors. Downregula-
tion of c-FLIP was monitored by western blot analysis at the
protein level (Figure 7b). It was most efficient when 10
multiplicities of infection (MOI) of viral vectors were applied,
but was also seen at 5 and 2 MOI. The weaker down-
regulation at lower MOI was attributed to fewer cells that had
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Figure 7. Role of c-FLIP for enhancement of apoptosis by diclofenac/HA. (a)
Apoptosis levels (DNA fragmentation) in HaCaT cells stably transduced with a
retroviral vector for c-FLIPL overexpression (HaCaT-FLIP) were compared with
those in mock-transduced cells (HaCaT-Mock). Both cell populations were
treated with death ligands for 16 hours (CH-11, TRAIL, TNF-a) or were left
untreated (). In addition, cells received diclofenac/HA (D/HA, 0.3%, for
20 hours, black bars) or were left untreated (gray). The relative values were
normalized with respect to the untreated HaCaT mock control (¼1). The inset
shows overexpression of FLIPL in HaCaT-FLIP cells as compared with that in
HaCaT-Mock. Two independent experiments were performed with triplicate
values both times; the means±SD of one experiment are shown here.
Reduction of apoptosis in HaCaT-FLIP cells was statistically significant
(Po0.05), as indicated by asterisks. (b) Expression of c-FLIPL (55 kDa) and
c-FLIPS (28 kDa) as determined by western blot analysis is shown in SCC-12
cells after transduction of lentiviral expression vectors for FLIPRNAi and
ScrambleRNAi. Non-transduced SCC-12 cells were included as controls (C).
Three approaches are shown with different MOIs (10, 5, 2). GAPDH served as
loading control. (c) Relative apoptosis (DNA fragmentation) are shown of
SCC-12 cells transduced with lentiviral expression vectors for FLIPRNAi or
ScrambleRNAi (MOI of 2 and 5). The cells received no additional treatment ()
or were treated with CH-11 or TRAIL for 8 hours. The values had been
normalized with respect to non-treated SCC-12 cells (¼ 1; not shown). Two
independent experiments were performed with triplicate values both times,
and the means±SD of one experiment are shown. Enhancement of death
ligand-mediated apoptosis in FLIPRNAi-treated cells as compared with that in
cells that received ScrambleRNAi was statistically significant (Po0.05), as
indicated by asterisks.
2104 Journal of Investigative Dermatology (2010), Volume 130
LF Fecker et al.
Apoptosis by Diclofenac/HA
been transduced. Transduction efficiencies were 60, 50, and
30% for FLIPRNAi (MOI¼10, 5, and 2) and at 80, 70, and
50% for ScrambleRNAi (data not shown). Clearly proving the
crucial role of c-FLIP for death ligand sensitivity in SCC cells,
downregulation of c-FLIP by short-hairpin RNA strongly
enhanced the sensitivity for CH-11 and TRAIL, as compared
with that in cells transduced with the scramble vector control.
At higher MOI, c-FLIP downregulation also resulted in
elevated apoptosis by itself (Figure 7c). Both experiments
together proved the crucial role of c-FLIP downregulation in
diclofenac/HA-mediated enhancement of apoptosis through
death ligands.
DISCUSSION
The prevalence of AK is increasing worldwide, demanding
the development of new and efficient treatments (Stockfleth
et al., 2008). NSAIDs are widely used in the clinic and they
also appear as highly promising for cancer prevention and
treatment (Cha and DuBois, 2007). High COX-2 expression is
a characteristic feature of epithelial skin cancer (An et al.,
2002; Nijsten et al., 2004; Muller-Decker and Furstenberger,
2007), and diclofenac/HA has been approved as treatment for
AK and has shown significant efficacy (Merk, 2007; Stock-
fleth et al., 2008). In a previous paper we have shown that
diclofenac is the active compound in diclofenac/HA and
responsible for induction of apoptosis (Fecker et al., 2007).
The effects of diclofenac on inhibition of the COX-2 pathway
have been extensively studied and its activity as an NSAID is
generally accepted (Mitchell et al., 1993; Johnsen et al.,
2004). Thus, inhibition of COX-2 appears to be the basis for
the induction of apoptosis. However, the downstream path-
ways in SCC cells were completely unclear.
Four SCC cells lines have been used in this study as model
for epithelial skin cancer, because of a general lack of AK cell
lines. Furthermore, AK is frequently assessed as an early stage
of invasive SCC (Quatresooz et al., 2008; Hauschild et al.,
2009), and similar pathway aberrations have been reported in
AK and SCC, particularly including the COX-2 pathway (An
et al., 2002; Muller-Decker and Furstenberger, 2007). The
SCC cell lines investigated here have been used in many
other laboratories and are generally accepted as representa-
tive for cutaneous skin cancer (Rheinwald and Beckett, 1981;
Tilgen et al., 1983; Schon et al., 2003). They have been
randomly selected for the experiments with no pre-selection.
Apoptosis is crucial for the mode of action of many
chemotherapeutics (Fulda and Debatin, 2006), and activity of
NSAIDs as well appears highly related to apoptosis induction
(Jana, 2008). The role of diclofenac in apoptosis regulation
has, however, been controversial. Even antiapoptotic effects
have been attributed as suppression of ER stress-induced
apoptosis in neuroblastoma cells (Yamazaki et al., 2006) and
inhibition of basal apoptosis in guinea-pig gastric mucous
cells (Ashton and Hanson, 2002).
In other cells, the proapoptotic activity of diclofenac was
clearly evident. Thus apoptosis induction in leukemia cells,
hepatocytes, and gastric epithelial cells was related to
alteration of mitochondrial function, generation of reactive
oxygen species, and caspase activation (Kusuhara et al.,
1999; Gomez-Lechon et al., 2003; Inoue et al., 2004). The
transcription factor NAG-1 (NSAID-activated gene) may
be further involved as shown in oral cavity cancer cells
(Kim et al., 2004). As for SCC cell lines, we have previously
shown induction of apoptosis by diclofenac/HA associated
with DNA fragmentation and caspase-3 activation (Fecker
et al., 2007). In addition, we show here activation of initiator
caspase-8 in response to diclofenac/HA treatment. Apoptosis
was further blocked by specific inhibitors for initiator
caspase-8 and caspase-10, indicating a crucial role of the
extrinsic apoptosis pathway.
A relation to death ligand sensitivity has so far not been
recognized for diclofenac-induced apoptosis and has even
been excluded as for hepatocytes (Gomez-Lechon et al.,
2003). Here, we present evidence that diclofenac/HA is most
efficient in SCC cells in enhancement of apoptosis through
death ligands TNF-a, CD95L, and TRAIL. To our knowledge,
the tight connection of diclofenac-induced apoptosis with
death receptor-dependent pathways was previously unre-
ported. The concentrations of diclofenac/HA used here
in vitro (0.2–0.3%) may also be achieved in the in vivo
situation, when considering a daily dose of 2 g of diclofenac/
HA recommended for treatment of a skin area of 100 cm2.
Death ligand-mediated, extrinsic pathways are of general
importance for an immune response when apoptosis is
induced by cytotoxic T-lymphocytes and natural killer cells
(Russell and Ley, 2002; Dauer et al., 2005). The decisive role
of the immune system in prevention of AK and subsequent
SCC is clearly evident in immune-suppressed patients (Ulrich
et al., 2006), and enhancement of cancer cells for an attack of
infiltrating lymphocytes is therefore of particular interest.
Furthermore, death ligands appear to be crucial in the
control of tissue homeostasis of normal keratinocytes, and the
CD95 control system is activated in response to UV
irradiation (Leverkus et al., 1997). Apoptosis by CD95 is
considered an important self-control and defense mechan-
isms against UV light-induced carcinogenesis in skin cells.
Thus downregulation of death ligand sensitivity is assumed to
be typical for SCC and AK (Bachmann et al., 2001; Filipowicz
et al., 2002; Rodust et al., 2009). Re-sensitization of tumor
cells may thus also re-install the self-control.
A relation to death ligand-induced apoptosis has not been
recognized for diclofenac/HA or diclofenac and not for
cutaneous carcinoma cells, but it has been discussed for
other NSAIDs and in other cellular models. Expression of
COX-2 itself was correlated to antiapoptotic effects and to
protection against CD95-induced apoptosis in hepatocytes
and in cholangiocarcinoma cells (Nzeako et al., 2002;
Casado et al., 2007). COX-2 overexpression also conferred
resistance to TRAIL-induced apoptosis in colon cancer cells
(Tang et al., 2002).
Enhancement of TRAIL-induced apoptosis has been shown
for celecoxib in glioma cells as well as in prostate, colon, and
lung cancer cells (Liu et al., 2006; Chen et al., 2007; Gaiser
et al., 2008; He et al., 2008). In pancreatic carcinoma and
hepatoma cells, COX-2 inhibitors were also shown to
increase CD95L sensitivity (Dauer et al., 2005; Kern et al.,
2006). Whether celecoxib may also enhance apoptosis by
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TNF-a was controversial (Kern et al., 2006; Yamanaka et al.,
2006).
Enhancement of TRAIL-mediated apoptosis by NSAIDs has
been occasionally related to decreased levels of survivin
(Gaiser et al., 2008; Lu et al., 2008). More frequently,
however, upregulation of TRAIL-R1/DR5 has been reported
after NSAID treatment, in particular after treatment with
celecoxib (Liu et al., 2006; Nakamoto et al., 2006; Yamanaka
et al., 2006; He et al., 2008). Also some upregulation of
CD95, TNF-R1, and DR4 surface expression has been
reported in hepatocellular carcinoma after COX-2 inhibition
by celecoxib (Kern et al., 2006), but these death receptors
were not involved in colon and prostate cancer cells after
sulindac sulfide treatment, where DR5 was selectively
upregulated (Huang et al., 2001). DR5 upregulation thus
appears to be a general mechanism of NSAID-mediated
apoptosis, whereas other receptors may be regulated in a
cell-specific manner. In SCC cells, however, upregulation of
death receptor surface expression in response to diclofenac/
HA treatment did not appear as crucial for their sensitivity.
Receptor clustering in cytoplasmic membrane rafts has been
discussed as an alternative way for regulation of death
receptor activity, but still appears to be controversial (Gulbins
and Kolesnick, 2003).
The apoptosis-enhancing effects of diclofenac/HA app-
eared also independent of p53, as there was no correlation of
sensitivity with the p53 mutation status in SCC cell lines or in
HaCaT cells. Here we report consistent downregulation of
c-FLIP isoforms (FLIPS and FLIPL) in response to diclofenac/
HA treatment of cutaneous SCC cells. The functional role of
c-FLIP for enhancement of death ligand-induced apoptosis by
diclofenac/HA was confirmed by two complementary strate-
gies. Thus, its overexpression abolished both death ligand-
induced apoptosis and the proapoptotic effects of diclofenac/
HA, and its short-hairpin RNA-mediated downregulation
enhanced death ligand-mediated apoptosis, similar to the
effects of diclofenac/HA.
A crucial role of c-FLIP in the down-modulation of
apoptosis through death ligands is frequently seen in
hematopoietic cancers such as Hodgkin lymphoma (Mathas
et al., 2004) and in cutaneous T-cell lymphoma (Braun et al.,
2007). No role for c-FLIP has so far been recognized in
diclofenac-mediated anticancer effects or for other NSAIDs in
SCC cells. But in normal keratinocytes, reduced TRAIL
sensitivity has been related to expression of c-FLIP (Leverkus
et al., 2000). Further connections to c-FLIP downregulation
have been identified for celecoxib in lung cancer cells (Liu
et al., 2006; Chen et al., 2007). The functional role was
proven by FLIPL overexpression, which inhibited apoptosis
induced by a combination of celecoxib and TRAIL (Liu et al.,
2006), similar to the overexpression experiments shown here.
Quick and efficient downregulation of antiapoptotic factors
such as survivin and c-FLIP in response to NSAID treatment
has been explained by enhanced proteasomal degradation
(Liu et al., 2006; Gaiser et al., 2008).
In conclusion, the data presented here show the proa-
poptotic activities of diclofenac/HA in epithelial skin cancer
cells. Diclofenac/HA by itself only weakly induced apoptosis,
but enhancement of death ligand-mediated apoptosis appea-
red as a main effect. Keeping in mind the important roles of
death ligands in the immune response and in the control of
keratinocyte homeostasis, a re-sensitization of SCC and AK
cells may have a crucial contribution to the therapeutic
effects of diclofenac/HA. A better understanding of its mode
of action will ultimately help to optimize clinical protocols.
MATERIALS AND METHODS
Cell lines and culture conditions
Six human cell lines were used in this present study: SCL-I, SCL-II,
SCC-12, and SCC-13 derived from facial SCC lesions (Rheinwald
and Beckett, 1981; Tilgen et al., 1983). HaCaT is a spontaneously
transformed keratinocyte cell line (Boukamp et al., 1988). The highly
CH-11-sensitive T-ALL cell line Jurkat (Schneider et al., 1977; Braun
et al., 2007) has been used as a positive control for apoptosis
induction. SCC cells were grown in RPMI medium supplemented
with 2mM glutamine and 1 non-essential amino acids; HaCaT
cells were grown in DMEM (4.5 g l1 glucose) and Jurkat cells were
grown in RPMI medium supplemented with 0.6mM glutamine.
Cultivation was performed at 371C and under 5% CO2, and growth
media were supplemented with 10% fetal calf serum.
For apoptotic and cytotoxicity assays, cells were seeded in six-
well (2.5 105 cellswell1), 24-well (6.5 104 cells per plate), or
48-well plates (2 104 cells per plate). Growth medium was
exchanged 24 hours after seeding and treatment was started. For
activation of extrinsic pathways, cells were treated with an agonistic
anti-CD95 antibody (CH-11, IgM mouse; Beckman Coulter, Krefeld,
Germany), with TRAIL (KillerTRAIL, soluble, human, recombinant;
Alexis, Gruenberg, Germany ALX-201-073-C020), or with TNF-a
(Sigma-Aldrich, Taufkirchen, Germany). The incubation time periods
were 16 hours (CH-11, TRAIL) or 24 hours (TNF-a) unless otherwise
indicated. The concentrations used for SCL-I, SCL-II, and SCC-13
were 100 ngml1 (CH-11) and 20 ngml1 (TRAIL). Other cells (SCC-
12, HaCaT, and Jurkat) showed much higher sensitivity to death
ligands, as determined in a concentration series, partially masking
the effects of diclofenac/HA. Thus for investigating a possible
enhancement of death ligand-induced apoptosis, concentrations of
death ligands were partly reduced: CH-11 was used at 1 ngml1
(SCC-12, Jurkat) and TRAIL was used at 10 ngml1 (SCC-12) or at
5 ngml1 (HaCaT). TNF-a was always used at 10 ngml1.
Diclofenac/HA (Almirall, Barcelona, Spain) was applied to cell
cultures at a final concentration of 0.2 or 0.3%. In the experiments,
when diclofenac/HA was substituted by diclofenac (Sigma-Aldrich),
it was used at an equimolar concentration of 90 mgml1. For
combined treatment, cells were pretreated for 4 hours with
diclofenac/HA, followed by diclofenac/HA and death ligands for
another 16 hours.
Analyses of cell death effects
Apoptosis was quantified by a cell death detection ELISA (Roche
Diagnostics, Mannheim, Germany), which detects mono- and
oligonucleosomes formed in apoptotic cells. Cytotoxicity was
determined in parallel by a lactate dehydrogenase release assay
(Roche Diagnostics), which determines the levels of lactate
dehydrogenase activity in culture supernatants corresponding to
the number of lysed cells. Relative apoptosis and cytotoxicity values
were calculated as compared with that of untreated controls. All
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protocols were performed as detailed by the supplier, with minor
modifications described previously (Eberle et al., 2003). Statistical
significance of apoptosis assays was determined by Student’s t-test
and P-values o0.05 were considered as statistically significant.
Cell-cycle analysis was performed for detection of hypodiploid
nuclei in flow cytometric analyses. After specific treatment, cells
were harvested by trypsinization, stained with propidium iodide
(200mgml1), and analysed by FACS (Nicoletti et al., 1991).
Growth rates were determined using a real-time cell analyzer
(xCELLigence; Roche diagnostics, Penzberg, Germany). This tech-
nique makes use of two microelectrodes integrated in each well of
special 96-well E-plates. The electric conductance between the
electrodes, which is dependent on the cell density, is continuously
measured. Cells were seeded in three different densities: 5,000;
10,000; and 20,000 cells per well. Treatment was started after
22 hours and conductance was continuously determined between 20
and 60 hours.
Viral transduction
HaCaT cells overexpressing c-FLIPL (HaCaT-FLIP) were generated
using a pEGZ retroviral vector containing c-FLIPL cDNA. Retroviral
transduction of HaCaT was performed as described previously
(Leverkus et al., 2003). Successfully transduced cells (polyclonal) were
selected with zeocin also as described previously (Armbruster et al.,
2009). Transduction and selection efficiency was monitored by flow
cytometric analysis for green fluorescent protein encoded by the
retroviral vector, and western blot analysis was used to confirm c-FLIPL
overexpression. Vector-transduced HaCaT cells served as controls.
Cloning of c-FLIP short-hairpin RNA and of a scramble control
sequence downstream from the U6 promoter in plasmid pLL3.7
(Rubinson et al., 2003) (Addgene, Cambridge, MA), as well as
construction of VSV-G pseudotyped replication-deficient lentiviral
vectors, was performed as described recently (Braun et al., 2010).
For transduction, SCC cells were seeded at a density of 2 104 cells
in 48-well plates. The next day, SCC-12 cells were incubated for
24 hours with lentiviral particles (MOI 10, 5, or 2) for expression of
c-FLIPRNAi or ScrambleRNAi. The culture medium was exchanged
and incubation was continued for another 24 hours under virus-free
culture conditions, before treatment with death ligands was started.
At 8 hours after treatment with death ligands, relative apoptosis was
determined by DNA fragmentation ELISA. Transduction efficiencies
were determined by flow cytometric analysis for the green
fluorescent protein encoded by the lentiviral vector.
Western blot analysis
For protein extraction, cells were seeded in 75-cm2 culture
flasks (2.5 106). Cells were harvested at 16 or 24 hours after
treatment, at a confluence of 60%–80%. Cells were washed with
phosphate-buffered saline (PBS) before lysis buffer was added. The
lysis buffer contained 50mM PIPES/HCl (pH 6.5), 2mM EDTA, 0.1%
Chaps, 40 mM leupeptin, 15 mM pepstatin, 10mgml1 trasylol, and
5mM dithiothreitol (New England Biolabs, Frankfurt am Main,
Germany).
For western blot analysis, cell lysates were homogenized and
centrifuged for 5minutes at 10,000 g. Equal protein amounts were
separated by electrophoresis under reducing conditions on 12 or
15% SDS-polyacrylamide gels, in parallel with a broad-range pre-
stained SDS-PAGE protein standard (Bio-Rad, Mu¨nchen, Germany).
Transfer of proteins to blotting membranes, ponceau staining, and
immunodetection of transferred proteins were performed as de-
scribed previously (Eberle et al., 2003).
The following antibodies were used: Cleaved caspase-3 (rabbit
polyclonal, 9661; New England Biolabs; 1:1,000); caspase-7 (mouse
monoclonal IgG, 9492; New England Biolabs; 1:1,000); caspase-8
(mouse monoclonal IgG, 9746; New England Biolabs; 1:1,000);
caspase-9 (rabbit polyclonal, 9502; New England Biolabs; 1:1,000);
caspase-10 (mouse monoclonal, M059; Biozol, Eching, Germany;
1:1,000); Bid (rabbit polyclonal, 2002; New England Biolabs;
1:1,000); c-FLIP (mouse monoclonal IgG, sc-5276; Santa Cruz
Biotechnology, Heidelberg, Germany; 1:600); b-actin (mouse
monoclonal, clone AC-15, Sigma-Aldrich, 1:10,000); a-tubulin
(rabbit polyclonal IgG, 2144; New England Biolabs; 1:1,000);
glyceraldehyde-3-phosphate dehydrogenase (mouse monoclonal
IgG, 6C5, sc-32233; Santa Cruz Biotechnology; 1:200). Two
secondary horseradish peroxidase-labeled antibodies were used
(horseradish peroxidase-labeled goat anti-rabbit immunoglobulins
and horseradish peroxidase-labeled goat anti-mouse immunoglobu-
lins; both from DakoCytomation, Hamburg, Germany, 1:5,000).
DNA sequence analysis for p53
Genomic DNA isolation from SCC and HaCaT cells was performed
using a QIAamp DNA Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. PCR amplification of
p53 exons 5, 7, and 8, as well as sequence analysis of amplified
DNA, was performed as described previously (Nindl et al., 2007).
The following primers were used for exon-5: TGTTCACTTGTG
CCCTGACT and AGCAATCAGTGAGGAATCAG; for exon-7: CTTG
CCACAGGTCTCCCCAA and AGGGGTCAGCGGCAAGCAGA; and
for exon-8: TTGGGAGTAGATGGAGCCT and AGAGGCAAGGAAA
GGTGATA.
Flow cytometry
For determination of DR4 and DR5 surface expression, cells were
harvested from culture plates by treatment with 0.02% EDTA in PBS.
After washing with PBS, aliquots of 5 105 cells in 100ml of PBS
with 1% BSA were incubated for 30minutes with an mAb against
TRAIL-R1/DR4 and TRAIL-R2/DR5, respectively (Alexis; HS101/
HS201, 1:100). The isotypic monoclonal mouse IgG1 antibody
(Alexis; clone MOPC31C, 278-010, 1:100) was used as a negative
control. After washing with PBS, cells were incubated for 30minutes
with the secondary phycoerythrin-labeled goat anti-mouse IgG1
antiserum (Alexis; 211-201-C050; 1:100). After washing with PBS,
surface expression was determined using a FACS-Calibur flow
cytometer (Becton Dickinson, Heidelberg, Germany). The mean
fluorescence index was calculated by using the CellQuest software
(Becton Dickinson).
CD95 surface expression was detected by FACS analysis of cells
incubated with a phycoerythrin-labeled monoclonal CD95 antibody
(clone DX2; Becton Dickinson, Heidelberg, Germany) as compared
with an isotypic-labeled IgG1 monoclonal control antibody (clone
MOPC-21; Becton Dickinson).
Caspase and death receptor inhibition
Irreversible caspase inhibitors (fluoromethyl ketone oligopeptides
(fmk); R&D Systems, Wiesbaden, Germany) were applied 1 hour
before the proapoptotic treatments started. They bind to the active
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sites of caspase-like proteases and thereby block their activity.
Inhibitors zVAD-fmk (pancaspase), zWEHD-fmk (caspase-1),
zVDVAD-fmk (caspase-2), zDEVD-fmk (caspase-3), zYVAD-fmk
(caspase-4), zVEID-fmk (caspase-6), zIETD-fmk (caspase-8),
zLEHD-fmk (caspase-9), and zAEVD-fmk (caspase-10) were used.
The inhibitors were applied at a final concentration of 10 mM.
For blocking TRAIL receptors, cells were seeded in 24-well plates
(5 104 cellswell1). After 24 hours, the growth medium was
replaced and 8mgml1 of the respective blocking antibody was
supplied (mouse monoclonal TRAIL-R1/DR4 and TRAIL-R2/DR5;
Alexis, clone HS101/HS 201). Treatment with diclofenac/HA (0.3%)
or with TRAIL (20 ngml1) started after 1 hour and was continued for
24 hours, before apoptosis was determined.
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